RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall

Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.

Zacks Investment Research • Oct 26, 2026

Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

Semaglutide supply reloading will begin by November 2026. Base business revenue grew double digits excluding North American Lenalidomide.

The Motley Fool • Oct 25, 2026

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.

MarketBeat • Oct 23, 2026

Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

Seeking Alpha • Oct 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).

PRNewsWire • Sep 24, 2026

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​for ​the promotion and ‌distribution ⁠of the Qdenga ​dengue ​vaccine ⁠in ​India.

Reuters • Sep 18, 2026

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN DR. REDDY'S LABORATORIES (RDY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal righ.

Business Wire • Aug 20, 2026

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY'S LABORATORIES (RDY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happ.

Business Wire • Aug 20, 2026

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY'S LABORATORIES (RDY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 22, 2026, Dr. Reddy's announced its first quart.

Business Wire • Aug 19, 2026

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)---- $RDY #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 22, 2026, Dr. Reddy's reported its first quarter earnings results for fiscal year 2027, r.

Business Wire • Aug 14, 2026